Intratumoral CD8⁺ T-cell differentiation is linked to durable HPV-specific immunity after neoadjuvant HPV vaccination with long-acting IL-7 and PD-1 blockade
Abstract Durable antigen-specific immunity is a goal of therapeutic vaccination, but its relationship to intratumoral CD8⁺ T-cell differentiation remains poorly defined. To address this question, we compared anti–PD-1, tirvalimogene teraplasmid (GX-188E), and long-acting IL-7 (GX-I7/NT-I7), alone and in combination, in HPV-positive tumor-bearing mice. Among tested regimens, triple immunotherapy produced the greatest tumor control and a pooled tumor profile enriched for stemness-associated intratumoral CD8⁺ states. We then evaluated the same components in a four-cohort phase 2 neoadjuvant study of 56 patients with resectable HPV-positive head and neck squamous cell carcinoma. In the 11-patient cohort receiving pembrolizumab, GX-188E, and NT-I7, 7 patients had a major pathologic response, including 4 with a pathologic complete response. To define the intratumoral immune program accompanying this activity, paired tumor profiling identified a GZMK⁺ effector-memory CD8⁺ state with cytotoxicity- and memory-associated features. GZMK⁺ effector-memory cells were prominent among T cells bearing clonotypes shared between post-treatment tumors and tumor-draining lymph nodes, consistent with intercompartmental recirculation. Higher tdLN Myc expression in both NT-I7-containing mouse profiles prompted regulatory analysis of the human GZMK⁺ state, revealing treatment-associated higher MYC and lower BATF regulon specificity; in silico IL7R perturbation was consistent with an IL-7-associated reprogramming model. Post-treatment intratumoral MYC-associated and relative MYC/BATF regulon measures were related to HPV16 E6/E7-reactive activation-induced marker responses at 2 years; in eight patients with paired tumors, treatment-associated relative MYC/BATF changes were separately related to a 2-year peptide-responsive CD8⁺ stem cell–like memory phenotype. Together, these findings associate intratumoral GZMK⁺ effector-memory remodeling with HPV-reactive activation and memory phenotypes 2 years later.
Authors
- Nam Suk Sim (ORCID: https://orcid.org/0000-0002-5567-8076)
- Min Hee Hong (ORCID: https://orcid.org/0000-0003-3490-2195)
- Eui‐Cheol Shin (ORCID: https://orcid.org/0000-0002-6308-9503)
- Sun Och Yoon (ORCID: https://orcid.org/0000-0002-5115-1402)
- Chang Ho Ahn (ORCID: https://orcid.org/0000-0002-0702-0608)
- Jonathan Gerald Goldin (ORCID: https://orcid.org/0000-0003-3007-9947)
- Hye Ryun Kim (ORCID: https://orcid.org/0000-0002-1842-9070)
- Chang Geol Lee
- Jinna Kim (ORCID: https://orcid.org/0000-0002-9978-4356)
- Yoon Woo Koh (ORCID: https://orcid.org/0000-0002-9734-1682)
- Yoon-Jeong Choi (ORCID: https://orcid.org/0000-0001-9714-6134)
- June‐Young Koh (ORCID: https://orcid.org/0000-0002-2043-6624)
- Kyung Hwan Kim (ORCID: https://orcid.org/0000-0002-6713-1350)
- Wonrak Son
- Jong-Eun Park (ORCID: https://orcid.org/0000-0002-1687-2423)
- Donghoon Choi (ORCID: https://orcid.org/0009-0005-7237-8779)
- DaHee Kim (ORCID: https://orcid.org/0009-0007-6660-7488)
- Yeju Kim
- Seungeun Lee (ORCID: https://orcid.org/0009-0007-6791-8296)
- Su-Hyung Park
- Chang Gon Kim
- Gamin Kim
Institutions
- Korea Advanced Institute of Science and Technology (KR)
- Yonsei University (KR)
- Severance Hospital (KR)
- University Health System (US)
- Gangnam Severance Hospital (KR)
- Yonsei University Health System (KR)
- Yonsei Cancer Hospital (KR)
- NeoImmuneTech, Inc. (United States) (US)
- Lunit (South Korea) (KR)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-12
- DOI
- https://doi.org/10.21203/rs.3.rs-11474333/v1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- preprint
Funders
- National Research Foundation
- Yonsei University
- Korea Health Industry Development Institute
- Ministry of Science and ICT, South Korea
- Yonsei University College of Medicine